View Item 

Show simple item record

Synthesis of Novel Peptide Inhibitors of Thrombin-induced Platelet Activation

dc.contributor.authorBurke, Fernanda Ferraccioli Marquesen_US
dc.contributor.authorWarnock, Marken_US
dc.contributor.authorSchmaier, Alvin H.en_US
dc.contributor.authorMosberg, Henry I.en_US
dc.date.accessioned2010-04-01T15:17:24Z
dc.date.available2010-04-01T15:17:24Z
dc.date.issued2006-11en_US
dc.identifier.citationBurke, Fernanda M.; Warnock, Mark; Schmaier, Alvin H.; Mosberg, Henry I. (2006). "Synthesis of Novel Peptide Inhibitors of Thrombin-induced Platelet Activation." Chemical Biology & Drug Design 68(5): 235-238. <http://hdl.handle.net/2027.42/65762>en_US
dc.identifier.issn1747-0277en_US
dc.identifier.issn1747-0285en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/65762
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17177882&dopt=citationen_US
dc.format.extent64620 bytes
dc.format.extent3110 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 The Authors Journal compilation 2006 Blackwell Munksgaarden_US
dc.subject.otherBradykininen_US
dc.subject.otherProtease-activated Receptoren_US
dc.subject.otherPlatelet Aggregationen_US
dc.subject.otherThrombinen_US
dc.subject.otherThrombin Receptoren_US
dc.titleSynthesis of Novel Peptide Inhibitors of Thrombin-induced Platelet Activationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, MI 48109-1065, USAen_US
dc.contributor.affiliationumDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0368, USAen_US
dc.contributor.affiliationotherDivision of Hematology/Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USAen_US
dc.identifier.pmid17177882en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/65762/1/j.1747-0285.2006.00442.x.pdf
dc.identifier.doi10.1111/j.1747-0285.2006.00442.xen_US
dc.identifier.sourceChemical Biology & Drug Designen_US
dc.identifier.citedreferencePaoli G., Merlini P.A., Ardissino D. ( 2005 ) Direct thrombin inhibitors for the treatment of acute coronary syndromes and during percutaneous coronary interventions. Curr Pharm Des ; 11 : 3919 – 3929.en_US
dc.identifier.citedreferenceChung A.W., Jurasz P., Hollenberg M.D., Radomski M.W. ( 2002 ) Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol ; 135 : 1123 – 1132.en_US
dc.identifier.citedreferenceCoughlin S.R. ( 2000 ) Thrombin signalling and protease-activated receptors. Nature ; 407 : 258 – 264.en_US
dc.identifier.citedreferenceCallahan K.P., Malinin A.I., Gurbel P.A., Alexander J.H., Granger C.B., Serebruany V.L. ( 2001 ) Platelet function and fibrinolytic agents: two sides of a coin ? Cardiology ; 95 : 55 – 60.en_US
dc.identifier.citedreferenceColman R.W., White J.V., Scovell S., Stadnicki A., Sartor R.B. ( 1999 ) Kininogens are antithrombotic proteins in vivo. Arterioscler Thromb Vasc Biol ; 19 : 2245 – 2250.en_US
dc.identifier.citedreferenceMurphey L.J., Hachey D.L., Oates J.A., Morrow J.D., Brown N.J. ( 2000 ) Metabolism of bradykinin in vivo in humans: identification of BK1–5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther ; 294 : 263 – 269.en_US
dc.identifier.citedreferenceHasan A.A., Warnock M., Srikanth S., Schmaier A.H. ( 2001 ) Developing peptide inhibitors to thrombin activation of platelets from bradykinin analogs. Thromb Res ; 104 : 451 – 465.en_US
dc.identifier.citedreferenceHasan A.A., Warnock M., Nieman M., Srikanth S., Mahdi F., Krishnan R. et al. ( 2003 ) Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol Heart Circ Physiol ; 285 : H183 – 193.en_US
dc.identifier.citedreferenceHasan A.A., Amenta S., Schmaier A.H. ( 1996 ) Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation ; 94 : 517 – 528.en_US
dc.identifier.citedreferenceNieman M.T., Warnock M., Hasan A.A., Mahdi F., Lucchesi B.R., Brown N.J. et al. ( 2004 ) The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. J Pharmacol Exp Ther ; 311 : 492 – 501.en_US
dc.identifier.citedreferenceBarany G., Merrifield R.B. ( 1980 ) The Peptides. Analysis, Synthesis, Biology. New York : Academic Press.en_US
dc.identifier.citedreferenceStewart J.M., Young J.D. ( 1984 ) Solid-Phase Peptide Synthesis, 2nd edn. Rockford, Illinois : Pierce Chemical Company.en_US
dc.identifier.citedreferenceFields G.B., Noble R.L. ( 1990 ) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res ; 35 : 161 – 214.en_US
dc.identifier.citedreferenceFields C.G., Lloyd D.H., Macdonald R.L., Otteson K.M., Noble R.L. ( 1991 ) HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res ; 4 : 95 – 101.en_US
dc.identifier.citedreferenceLembeck F., Griesbacher T., Eckhardt M., Henke S., Breipohl G., Knolle J. ( 1991 ) New, long-acting, potent bradykinin antagonists. Br J Pharmacol ; 102 : 297 – 304.en_US
dc.identifier.citedreferenceStewart J.M. ( 2004 ) Bradykinin antagonists: discovery and development. Peptides ; 25 : 527 – 532.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1747-0285.2006.00442.x.pdf
Size:
63.10KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.